Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis

John N Galgiani, Neil M. Ampel, Janis E. Blair, Antonino Catanzaro, Francesca Geertsma, Susan E. Hoover, Royce H. Johnson, Shimon Kusne, Jeffrey R Lisse, Joel D. MacDonald, Shari L. Meyerson, Patricia B. Raksin, John Siever, David A. Stevens, Rebecca Sunenshine, Nicholas Theodore

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.

Original languageEnglish (US)
Pages (from-to)717-722
Number of pages6
JournalClinical Infectious Diseases
Volume63
Issue number6
DOIs
StatePublished - Sep 15 2016

Fingerprint

Coccidioidomycosis
Practice Guidelines
Infection
Southwestern United States
Physicians
Guideline Adherence
Lung
Therapeutics
Guidelines

Keywords

  • antifungal treatment
  • coccidioidomycosis
  • community acquired pneumonia
  • immunocompromised patients
  • travel history

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Executive Summary : 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. / Galgiani, John N; Ampel, Neil M.; Blair, Janis E.; Catanzaro, Antonino; Geertsma, Francesca; Hoover, Susan E.; Johnson, Royce H.; Kusne, Shimon; Lisse, Jeffrey R; MacDonald, Joel D.; Meyerson, Shari L.; Raksin, Patricia B.; Siever, John; Stevens, David A.; Sunenshine, Rebecca; Theodore, Nicholas.

In: Clinical Infectious Diseases, Vol. 63, No. 6, 15.09.2016, p. 717-722.

Research output: Contribution to journalReview article

Galgiani, JN, Ampel, NM, Blair, JE, Catanzaro, A, Geertsma, F, Hoover, SE, Johnson, RH, Kusne, S, Lisse, JR, MacDonald, JD, Meyerson, SL, Raksin, PB, Siever, J, Stevens, DA, Sunenshine, R & Theodore, N 2016, 'Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis', Clinical Infectious Diseases, vol. 63, no. 6, pp. 717-722. https://doi.org/10.1093/cid/ciw538
Galgiani, John N ; Ampel, Neil M. ; Blair, Janis E. ; Catanzaro, Antonino ; Geertsma, Francesca ; Hoover, Susan E. ; Johnson, Royce H. ; Kusne, Shimon ; Lisse, Jeffrey R ; MacDonald, Joel D. ; Meyerson, Shari L. ; Raksin, Patricia B. ; Siever, John ; Stevens, David A. ; Sunenshine, Rebecca ; Theodore, Nicholas. / Executive Summary : 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. In: Clinical Infectious Diseases. 2016 ; Vol. 63, No. 6. pp. 717-722.
@article{433d7b1348fd4778a01e734c24887900,
title = "Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis",
abstract = "It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.",
keywords = "antifungal treatment, coccidioidomycosis, community acquired pneumonia, immunocompromised patients, travel history",
author = "Galgiani, {John N} and Ampel, {Neil M.} and Blair, {Janis E.} and Antonino Catanzaro and Francesca Geertsma and Hoover, {Susan E.} and Johnson, {Royce H.} and Shimon Kusne and Lisse, {Jeffrey R} and MacDonald, {Joel D.} and Meyerson, {Shari L.} and Raksin, {Patricia B.} and John Siever and Stevens, {David A.} and Rebecca Sunenshine and Nicholas Theodore",
year = "2016",
month = "9",
day = "15",
doi = "10.1093/cid/ciw538",
language = "English (US)",
volume = "63",
pages = "717--722",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Executive Summary

T2 - 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis

AU - Galgiani, John N

AU - Ampel, Neil M.

AU - Blair, Janis E.

AU - Catanzaro, Antonino

AU - Geertsma, Francesca

AU - Hoover, Susan E.

AU - Johnson, Royce H.

AU - Kusne, Shimon

AU - Lisse, Jeffrey R

AU - MacDonald, Joel D.

AU - Meyerson, Shari L.

AU - Raksin, Patricia B.

AU - Siever, John

AU - Stevens, David A.

AU - Sunenshine, Rebecca

AU - Theodore, Nicholas

PY - 2016/9/15

Y1 - 2016/9/15

N2 - It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.

AB - It is important to realize that guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. Infectious Diseases Society of America considers adherence to these guidelines to be voluntary, with the ultimate determination regarding their application to be made by the physician in the light of each patient's individual circumstances. Coccidioidomycosis, also known as San Joaquin Valley fever, is a systemic infection endemic to parts of the southwestern United States and elsewhere in the Western Hemisphere. Residence in and recent travel to these areas are critical elements for the accurate recognition of patients who develop this infection. In this practice guideline, we have organized our recommendations to address actionable questions concerning the entire spectrum of clinical syndromes. These can range from initial pulmonary infection, which eventually resolves whether or not antifungal therapy is administered, to a variety of pulmonary and extrapulmonary complications. Additional recommendations address management of coccidioidomycosis occurring for special at-risk populations. Finally, preemptive management strategies are outlined in certain at-risk populations and after unintentional laboratory exposure.

KW - antifungal treatment

KW - coccidioidomycosis

KW - community acquired pneumonia

KW - immunocompromised patients

KW - travel history

UR - http://www.scopus.com/inward/record.url?scp=84995468053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995468053&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw538

DO - 10.1093/cid/ciw538

M3 - Review article

C2 - 27559032

AN - SCOPUS:84995468053

VL - 63

SP - 717

EP - 722

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 6

ER -